Literature DB >> 6807543

Parenteral formulation of hexamethylmelamine potentially suitable for use in man.

M M Ames, J S Kovach.   

Abstract

We have developed a preparation of hexamethylmelamine (HMM), dissolved in a fat emulsion Intralipid 20%, that is potentially satisfactory for parenteral administration to man. Solid HMM can be dissolved in Intralipid 20% up to 5 mg/ml, with extensive agitation. Solubilization of HMM is facilitated first by dissolving the drug in ethanol or in dimethylacetamide and then by adding the solution to Intralipid 20%. The disposition of HMM in rabbits after iv administration of HMM dissolved in Intralipid 20% was similar to the disposition of the drug following iv administration of HMM dissolved in 0.1 N HCl.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6807543

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  8 in total

Review 1.  Injectable lipid emulsions-advancements, opportunities and challenges.

Authors:  Ketan Hippalgaonkar; Soumyajit Majumdar; Viral Kansara
Journal:  AAPS PharmSciTech       Date:  2010-10-26       Impact factor: 3.246

Review 2.  Anticancer drug pharmacodynamics.

Authors:  G Powis
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

Review 3.  Developing new drugs for ovarian cancer: a challenging task in a changing reality.

Authors:  R M Canetta; S K Carter
Journal:  J Cancer Res Clin Oncol       Date:  1984       Impact factor: 4.553

4.  Regional targeting of bisantrene by directed intravascular precipitation.

Authors:  J S Kovach; M Buck; T Tsukamoto; A Odegaard; M M Lieber
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

5.  Pharmacokinetic study of methyl glyoxal-bis-guanylhydrazone (methyl-GAG).

Authors:  M Slavik; T Clouse; A Wood; O Blanc; R C Eschbach
Journal:  Invest New Drugs       Date:  1983       Impact factor: 3.850

6.  Effect of a hepatic activation system on the antiproliferative activity of hexamethylmelamine against human tumor cell lines.

Authors:  K J Miller; R M McGovern; M M Ames
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

7.  Phase II trial of intravenous hexamethylmelamine in patients with advanced ovarian cancer.

Authors:  M D Hauge; H J Long; L C Hartmann; J H Edmonson; M J Webb; J Su
Journal:  Invest New Drugs       Date:  1992-11       Impact factor: 3.850

Review 8.  Clinical pharmacokinetics of altretamine.

Authors:  G Damia; M D'Incalci
Journal:  Clin Pharmacokinet       Date:  1995-06       Impact factor: 6.447

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.